Title |
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
|
---|---|
Published in |
Trials, March 2011
|
DOI | 10.1186/1745-6215-12-62 |
Pubmed ID | |
Authors |
Peter Connick, Madhan Kolappan, Rickie Patani, Michael A Scott, Charles Crawley, Xiao-Ling He, Karen Richardson, Kelly Barber, Daniel J Webber, Claudia AM Wheeler-Kingshott, Daniel J Tozer, Rebecca S Samson, David L Thomas, Ming-Qing Du, Shi L Luan, Andrew W Michell, Daniel R Altmann, Alan J Thompson, David H Miller, Alastair Compston, Siddharthan Chandran |
Abstract |
No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes--the "sentinel lesion approach". |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | <1% |
Turkey | 1 | <1% |
India | 1 | <1% |
Germany | 1 | <1% |
Unknown | 202 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 63 | 30% |
Student > Ph. D. Student | 26 | 13% |
Researcher | 25 | 12% |
Student > Bachelor | 18 | 9% |
Other | 12 | 6% |
Other | 31 | 15% |
Unknown | 32 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 55 | 27% |
Agricultural and Biological Sciences | 26 | 13% |
Nursing and Health Professions | 25 | 12% |
Biochemistry, Genetics and Molecular Biology | 13 | 6% |
Neuroscience | 13 | 6% |
Other | 36 | 17% |
Unknown | 39 | 19% |